巨噬细胞M2标志物CD163和MRC1在急性髓性白血病中的预后分析

打开文本图片集

DOI：10.3969/j.issn.1006-1959.2025.07.001 文章编号：1006-1959（2025）07-0001-09

Abstract：ObectiTvestigaetfofteexprsiooftmoasoatedmacoM（-TAs）markersCDndote survivalandprognosisofacutemyeloidleukemia（AML）MethodsPan-canceranalysisofCD163andMRC1wasperformedbyTCGAand UALCAN.TAEplerdealeapdl prognosisfCD16andMRClinAMLTheSCHdatabasewasusedtoaalyzeCD163andMRC1atthesinglecellevel.ResultsTheepreion fMRC1wasoeglatedinosortissusndteexpressoofC63inotissssgertantatintsss BysearchingCGAGEUNKaplaeeroedlcabssdhathali withhighexpressonofC16adC1wasshorethanthatoflwexpressongoupichwasaigiskfactorandeieeas statistically significant .InthesinglecelldatasetAML_GSE116256，it was found thatCD163 was mainlyexpressed inmononuclear macropgespdoseldaltdsu TAMswasverifdyellplaleatioduoeseCocusioompadihalttrolstitsa highexpressofCD163andMRC1，andatientswithghM2TAMsinfiltrtionaveaoorprogosisCD63ndMRC1wereprelarily demonstrated as potential prognostic indicators in AML.

Keywords：Acute myeloid leukemia；M2-tumor-associated macrophages；CD163；MRC1

急性髓性白血病（acutemyeloid leukemia，AML）是一种异质性血液系统疾病。（剩余10678字）